Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue growth forecast to 15-25%, up from the previous guidance of up to 10%, driven by new product launches and geographic diversification. Moderna's next-generation mRNA Covid vaccine and new flu shot are contributing to growth, alongside strong international sales and long-term government contracts. The company also highlighted promising data on its personalized cancer vaccine in partnership with Merck, despite some initial market volatility.
Moderna's market capitalization stands at $96.40 billion with a trading volume of 11,879,068 shares as of November 6, 2026, 18:41 WIB. Despite the company's raised revenue growth forecast, its stock price on Pluang is down 1.74% at USD 237.25. Meanwhile, Merck, a partner in Moderna's personalized cancer vaccine project, has a market cap of $362.24 billion and a dividend yield of 2.31%, with its stock down 1.86% at USD 144.21 as of the same time. Pluang investors show a stronger buying interest in Moderna, with 68% buy orders compared to 32% sell orders.
On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...
Moderna's stock is rated Strong Sell at $220.83, with a valuation around $60 per share, implying a 73% downside. This is despite promising Phase 3 melanoma trial results showing a 42% reduction in relapse or death when using intismeran with Keytruda....
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
